Your browser doesn't support javascript.
loading
The Spatial Extracellular Proteomic Tumor Microenvironment Distinguishes Molecular Subtypes of Hepatocellular Carcinoma.
Macdonald, Jade K; Taylor, Harrison B; Wang, Mengjun; Delacourt, Andrew; Edge, Christin; Lewin, David N; Kubota, Naoto; Fujiwara, Naoto; Rasha, Fahmida; Marquez, Cesia A; Ono, Atsushi; Oka, Shiro; Chayama, Kazuaki; Lewis, Sara; Taouli, Bachir; Schwartz, Myron; Fiel, M Isabel; Drake, Richard R; Hoshida, Yujin; Mehta, Anand S; Angel, Peggi M.
Afiliación
  • Macdonald JK; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina 29425, United States.
  • Taylor HB; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina 29425, United States.
  • Wang M; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina 29425, United States.
  • Delacourt A; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina 29425, United States.
  • Edge C; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina 29425, United States.
  • Lewin DN; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina 29425, United States.
  • Kubota N; Liver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.
  • Fujiwara N; Liver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.
  • Rasha F; Liver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.
  • Marquez CA; Liver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.
  • Ono A; Department of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
  • Oka S; Department of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
  • Chayama K; Hiroshima Institute of Life Sciences, Hiroshima 734-8553, Japan.
  • Lewis S; Collaborative Research Laboratory of Medical Innovation, Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima 734-8553, Japan.
  • Taouli B; RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
  • Schwartz M; Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Fiel MI; Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Drake RR; Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Hoshida Y; Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Mehta AS; Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Angel PM; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
J Proteome Res ; 2024 Jul 09.
Article en En | MEDLINE | ID: mdl-38980715
ABSTRACT
Hepatocellular carcinoma (HCC) mortality rates continue to increase faster than those of other cancer types due to high heterogeneity, which limits diagnosis and treatment. Pathological and molecular subtyping have identified that HCC tumors with poor outcomes are characterized by intratumoral collagenous accumulation. However, the translational and post-translational regulation of tumor collagen, which is critical to the outcome, remains largely unknown. Here, we investigate the spatial extracellular proteome to understand the differences associated with HCC tumors defined by Hoshida transcriptomic subtypes of poor outcome (Subtype 1; S1; n = 12) and better outcome (Subtype 3; S3; n = 24) that show differential stroma-regulated pathways. Collagen-targeted mass spectrometry imaging (MSI) with the same-tissue reference libraries, built from untargeted and targeted LC-MS/MS was used to spatially define the extracellular microenvironment from clinically-characterized, formalin-fixed, paraffin-embedded tissue sections. Collagen α-1(I) chain domains for discoidin-domain receptor and integrin binding showed distinctive spatial distribution within the tumor microenvironment. Hydroxylated proline (HYP)-containing peptides from the triple helical regions of fibrillar collagens distinguished S1 from S3 tumors. Exploratory machine learning on multiple peptides extracted from the tumor regions could distinguish S1 and S3 tumors (with an area under the receiver operating curve of ≥0.98; 95% confidence intervals between 0.976 and 1.00; and accuracies above 94%). An overall finding was that the extracellular microenvironment has a high potential to predict clinically relevant outcomes in HCC.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Proteome Res Asunto de la revista: BIOQUIMICA Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Proteome Res Asunto de la revista: BIOQUIMICA Año: 2024 Tipo del documento: Article